Evidence map›Paper›PMID 40649308›Full record

ArticleMolecules (Basel, Switzerland)2025

A Novel HDAC6 Inhibitor Enhances the Efficacy of Paclitaxel Against Ovarian Cancer Cells.

An-Jui Chi, Jui-Ling Hsu, Yun-Xin Xiao, Ji-Wang Chern, Jih-Hwa Guh, Chao-Wu Yu, Lih-Ching Hsu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

An-Jui ChiSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.
Jui-Ling HsuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.
Yun-Xin XiaoSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.
Ji-Wang ChernSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.
Jih-Hwa GuhSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.ORCID 0000-0002-6738-6054
Chao-Wu YuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.ORCID 0000-0002-5176-4225
Lih-Ching HsuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.

Funding

the Ministry of Science and Technology in Taiwan MOST 109-2320-B-002-048)
6 · The paper itself

Abstract

Ovarian cancer cells overexpress HDAC6, and selective HDAC6 inhibitors have been considered potential new drugs for ovarian cancer either alone or in combination with other anticancer agents. We screened 46 potential novel HDAC6 inhibitors in ES-2 ovarian cancer cells and showed that compound

Indexed as

Histone Deacetylase 6Histone Deacetylase InhibitorsOvarian NeoplasmsPaclitaxelApoptosisCell Line, TumorCell MovementCell ProliferationDrug SynergismFemaleHumansTubulinHDAC6 protein, humanHistone Deacetylase 6Histone Deacetylase InhibitorsPaclitaxelTubulinapoptosiscombination therapyHDAC6 inhibitorovarian cancerpaclitaxel (Taxol)

Identifiers

PMID40649308
PMCPMC12251222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.